Literature DB >> 26843101

Circulating matrix metalloproteinases in children with diabetic ketoacidosis.

Aris Garro1,2, Adam Chodobski2, Joanna Szmydynger-Chodobska2, Rongzi Shan2, Shara R Bialo1,2, Jonathan Bennett3, Kimberly Quayle4, Arleta Rewers5, Jeffrey E Schunk6, T Charles Casper6, Nathan Kuppermann7, Nicole Glaser8.   

Abstract

BACKGROUND AND
OBJECTIVE: Matrix metalloproteinases (MMPs) mediate blood-brain barrier dysfunction in inflammatory disease states. Our objective was to compare circulating MMPs in children with diabetic ketoacidosis (DKA) to children with type 1 diabetes mellitus without DKA. RESEARCH DESIGN AND METHODS: This was a prospective study performed at five tertiary-care pediatric hospitals. We measured plasma MMP-2, MMP-3, and MMP-9 early during DKA (time 1; within 2 h of beginning intravenous fluids) and during therapy (time 2; median 8 h; range: 4-16 h). The primary outcome was MMP levels in 34 children with DKA vs. 23 children with type 1 diabetes without DKA. Secondary outcomes included correlations between MMPs and measures of DKA severity.
RESULTS: In children with DKA compared with diabetes controls, circulating MMP-2 levels were lower (mean 77 vs. 244 ng/mL, p < 0.001), MMP-3 levels were similar (mean 5 vs. 4 ng/mL, p = 0.57), and MMP-9 levels were higher (mean 67 vs. 25 ng/mL, p = 0.002) early in DKA treatment. MMP-2 levels were correlated with pH at time 1 (r = 0.45, p = 0.018) and time 2 (r = 0.47, p = 0.015) and with initial serum bicarbonate at time 2 (r = 0.5, p = 0.008). MMP-9 levels correlated with hemoglobin A1c in DKA and diabetes controls, but remained significantly elevated in DKA after controlling for hemoglobin A1c (β = -31.3, p = 0.04).
CONCLUSIONS: Circulating MMP-2 levels are lower and MMP-9 levels are higher in children during DKA compared with levels in children with diabetes without DKA. Alterations in MMP expression could mediate BBB dysfunction occurring during DKA.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biomarkers; cerebral edema; cerebral injury; type 1 diabetes mellitus

Mesh:

Substances:

Year:  2016        PMID: 26843101      PMCID: PMC4974171          DOI: 10.1111/pedi.12359

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  44 in total

1.  Acute activation of peripheral lymphocytes during treatment of diabetic ketoacidosis.

Authors:  W H Hoffman; S W Helman; G Passmore
Journal:  J Diabetes Complications       Date:  2001 May-Jun       Impact factor: 2.852

Review 2.  The blood-brain barrier/neurovascular unit in health and disease.

Authors:  Brian T Hawkins; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

3.  Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions.

Authors:  Mira Lischper; Simon Beuck; Gokulan Thanabalasundaram; Christian Pieper; Hans-Joachim Galla
Journal:  Brain Res       Date:  2010-03-01       Impact factor: 3.252

4.  Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics.

Authors:  N Glaser; P Barnett; I McCaslin; D Nelson; J Trainor; J Louie; F Kaufman; K Quayle; M Roback; R Malley; N Kuppermann
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

Review 5.  Matrix metalloproteinases in neuroinflammation.

Authors:  Gary A Rosenberg
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

6.  Diabetic ketoacidosis elicits systemic inflammation associated with cerebrovascular endothelial cell dysfunction.

Authors:  Taylor E Close; Gediminas Cepinskas; Tatsushi Omatsu; Keeley L Rose; Kelly Summers; Eric K Patterson; Douglas D Fraser
Journal:  Microcirculation       Date:  2013-08       Impact factor: 2.628

7.  Subclinical brain swelling in children during treatment of diabetic ketoacidosis.

Authors:  E J Krane; M A Rockoff; J K Wallman; J I Wolfsdorf
Journal:  N Engl J Med       Date:  1985-05-02       Impact factor: 91.245

Review 8.  Matrix metalloproteinases in immunity.

Authors:  E J Goetzl; M J Banda; D Leppert
Journal:  J Immunol       Date:  1996-01-01       Impact factor: 5.422

9.  Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies.

Authors:  Solveig Horstmann; Pamela Kalb; James Koziol; Humphrey Gardner; Simone Wagner
Journal:  Stroke       Date:  2003-08-07       Impact factor: 7.914

10.  MMP9 deficiency does not decrease blood-brain barrier disruption, but increases astrocyte MMP3 expression during viral encephalomyelitis.

Authors:  Carine Savarin; Stephen A Stohlman; Anna M Rietsch; Niranjan Butchi; Richard M Ransohoff; Cornelia C Bergmann
Journal:  Glia       Date:  2011-07-28       Impact factor: 7.452

View more
  7 in total

1.  Intracerebral matrix metalloproteinase 9 in fatal diabetic ketoacidosis.

Authors:  William H Hoffman; Cornelia D Cudrici; Dallas Boodhoo; Alexandru Tatomir; Violeta Rus; Horea Rus
Journal:  Exp Mol Pathol       Date:  2019-04-13       Impact factor: 3.362

2.  Effects of TRAM-34 and minocycline on neuroinflammation caused by diabetic ketoacidosis in a rat model.

Authors:  Nicole Glaser; Steven Chu; Justin Weiner; Linnea Zdepski; Heike Wulff; Daniel Tancredi; Martha E ODonnell
Journal:  BMJ Open Diabetes Res Care       Date:  2022-05

3.  Cognitive Function Following Diabetic Ketoacidosis in Children With New-Onset or Previously Diagnosed Type 1 Diabetes.

Authors:  Simona Ghetti; Nathan Kuppermann; Arleta Rewers; Sage R Myers; Jeff E Schunk; Michael J Stoner; Aris Garro; Kimberly S Quayle; Kathleen M Brown; Jennifer L Trainor; Leah Tzimenatos; Andrew D DePiero; Julie K McManemy; Lise E Nigrovic; Maria Y Kwok; Clinton S Perry; Cody S Olsen; T Charles Casper; Nicole S Glaser
Journal:  Diabetes Care       Date:  2020-09-22       Impact factor: 19.112

4.  Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.

Authors:  Nathan Kuppermann; Simona Ghetti; Jeff E Schunk; Michael J Stoner; Arleta Rewers; Julie K McManemy; Sage R Myers; Lise E Nigrovic; Aris Garro; Kathleen M Brown; Kimberly S Quayle; Jennifer L Trainor; Leah Tzimenatos; Jonathan E Bennett; Andrew D DePiero; Maria Y Kwok; Clinton S Perry; Cody S Olsen; T Charles Casper; J Michael Dean; Nicole S Glaser
Journal:  N Engl J Med       Date:  2018-06-14       Impact factor: 91.245

Review 5.  The Impact of Microbiota-Gut-Brain Axis on Diabetic Cognition Impairment.

Authors:  Youhua Xu; Hua Zhou; Quan Zhu
Journal:  Front Aging Neurosci       Date:  2017-04-27       Impact factor: 5.750

6.  Frequency and Risk Factors of Acute Kidney Injury During Diabetic Ketoacidosis in Children and Association With Neurocognitive Outcomes.

Authors:  Sage R Myers; Nicole S Glaser; Jennifer L Trainor; Lise E Nigrovic; Aris Garro; Leah Tzimenatos; Kimberly S Quayle; Maria Y Kwok; Arleta Rewers; Michael J Stoner; Jeff E Schunk; Julie K McManemy; Kathleen M Brown; Andrew D DePiero; Cody S Olsen; T Charles Casper; Simona Ghetti; Nathan Kuppermann
Journal:  JAMA Netw Open       Date:  2020-12-01

Review 7.  Application of bench studies at the bedside to improve outcomes in the management of severe diabetic ketoacidosis in children-a narrative review.

Authors:  Namita Ravikumar; Arun Bansal
Journal:  Transl Pediatr       Date:  2021-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.